

**Integrated Diagnostics Holdings Plc**

**1H 2024 Results**

Wednesday, 28 August 2024

## Integrated Diagnostics Holdings plc delivers strong 33% y on-year revenue growth in 1H 2024

**(Cairo and London)** - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading provider of diagnostic services with operations in Egypt, Jordan, Nigeria, Sudan and Saudi Arabia, announced today its unaudited financial statements for the six-month period ended 30 June 2024. IDH recorded revenues of EGP 2,498 million, a 33% increase year-on-year driven by higher test volumes and increased average revenues per test. Strong operational performance, combined with IDH's ongoing cost optimization efforts, has improved profitability across the board. The Group posted an EBITDA of EGP 668 million, up 45% year-on-year, with an increased EBITDA margin of 27% compared to 25% in 1H 2023. Additionally, the company saw significant net profit growth of 127% year-on-year, reaching EGP 197 million and achieving an expanded net profit margin (NPM) of 19%.

On a quarterly basis, revenues reached EGP 1,327 million in Q2 2024, representing a 39% increase year-on-year. Net profit saw substantial growth, rising 84% year-on-year to total EGP 78 million.

### Financial Results (IFRS)

EGP mn	Q2 2023	Q2 2024	Change
<b>Revenues</b>	<b>957</b>	<b>1,327</b>	<b>39%</b>
Cost of Sales	(623)	(831)	33%
<b>Gross Profit</b>	<b>333</b>	<b>497</b>	<b>49%</b>
<i>Gross Profit Margin</i>	34.8%	37.4%	2.6 pts
Operating Profit	136	215	57%
<b>EBITDA<sup>[1]</sup></b>	<b>234</b>	<b>338</b>	<b>44%</b>
<i>EBITDA Margin</i>	24.5%	25.4%	0.9 pts
<b>Net Profit</b>	<b>43</b>	<b>78</b>	<b>84%</b>
<i>Net Profit Margin</i>	4.5%	5.9%	1.4 pts
<b>Cash Balance<sup>[2]</sup></b>	<b>666</b>	<b>1,254</b>	<b>88%</b>

Note: Throughout the document, percentage changes are calculated using the exact value (as per the Consolidated Financials) and not the corresponding rounded figure.

### Key Operational Indicators<sup>[3]</sup>

EGP mn	1H 2023
Branches	588
Patients ('000)	3,917
Revenue per Patient (EGP)	478
Tests ('000)	16,465
Revenue per Test	114
Test per Patient	4.2


## Introduction

### i. Financial Highlights

- IDH recorded **consolidated revenues** of EGP 2,498 million in the first half of 2024, increasing 33% year-on-year from EGP 1,872 million in 1H 2023. Growth was supported by an 8% year-on-year rise in test volume and a 23% year-on-year increase in average revenue per test. On a three-month basis, IDH's consolidated revenues grew 39% year-on-year to EGP 1,327 million.

**Revenue Progression**  
(EGP mn)

**Test Volume**



- **Gross profit** for the six-month period recorded EGP 925 million, reflecting a 41% increase from EGP 656 million in 1H 2023. The gross profit margin stood at 37% in 1H 2024, up from 35% in the same period last year, underscoring the effectiveness of IDH's cost optimization efforts. On a quarterly basis, gross profit recorded EGP 497 million, up 49% year-on-year, with a higher margin of 37% versus 35% in Q2 2023.
- **EBITDA** recorded EGP 668 million in the first half of 2024, up 45% from EGP 462 million in the same period last year. The EBITDA margin improved to 27% from 25% in 1H 2023. Higher EBITDA profitability was driven by revenue growth that outpaced the rise in costs and SG&A expenses. Moreover, IDH continued to implement cost optimization efforts amid inflationary pressures, which reflect positively on margins. In Q2 2024, EBITDA came in at EGP 338 million, up 44% year-on-year with a stable margin of 25%.
- **Net profit** for 1H 2024 reached EGP 480 million, representing a notable 127% year-on-year increase from EGP 165 million in 1H 2023. The Net Profit Margin (NPM) expanded to 19%, up 8 percentage points from the 11% recorded in 1H 2023. On a quarterly basis, net profit grew 84% year-on-year to EGP 78 million, with an associated net profit margin of 6%, up from 4% in the same period of the previous year.

### ii. Operational Highlights

- At the end of 1H 2024, **IDH's branch network** stood at 591 branches, up by 3 branches compared to the end of 1H 2023. In the first half of the year, IDH launched 20 new branches in Egypt and two inaugural branches in Saudi Arabia. During the same period, IDH closed one of its branches in Jordan located in Jordan's airport due to a decrease in testing following the COVID-19 pandemic, as well as all 18 branches in Sudan due to the conflict.

- During the first half of the year, IDH conducted 17.8 million **tests** across its geographies, reflecting year-on-year increase from 16.5 million tests in 1H 2023.
- The **average revenue per test** reached EGP 140 in 1H 2024, up 23% compared to EGP 114 in 1H 2023. This increase was largely attributed to strategic price increases introduced by IDH to address inflationary pressures in its primary markets, including Egypt and Nigeria.
- During the first half of 2024, IDH served 4.1 million **patients**, up 5% year-on-year, with the average number of tests per patient reaching a record-high of 4.3, highlighting the success of IDH's strategies to attract and retain patients while promoting increased testing. The continued rise in average tests per patient underscores the effectiveness of IDH's initiatives, including its loyalty program introduced in FY 2021, which remains a key driver in enhancing patient testing.

### iii. Updates by Geography

- In **Egypt** (82.8% of total revenues in 1H 2024), IDH saw significant growth during the first half of 2024, generating EGP 2,069 million in revenues, up 37% year-on-year. Revenue growth was primarily fuelled by a 23% year-on-year rise in the average revenue per test, reaching EGP 125 in 1H 2024, and further strengthened by a 10% year-on-year expansion in test volumes, with IDH conducting 16.5 million tests in the first half of 2024. On a quarterly basis, IDH's Egyptian operations recorded revenues of EGP 1,080 million in Q2 2024, an increase of 38% year-on-year.
- IDH's **Jordanian** subsidiary (15.4% of total revenues in 1H 2024), Biolab, recorded revenues of EGP 540 million, down 4% year-on-year, largely attributed to a 2% reduction in test volumes during 1H 2024 as a result of the ongoing geopolitical situation in the region. The average revenue per test in Jordan declined a marginal 1% year-on-year during the period due to stringent pricing regulations imposed on Jordan's health sector. In EGP terms, operations in Jordan reported revenues of EGP 386 million, representing a 33% year-on-year increase due to the translation effect from a weakened EGP.
- In **Nigeria** (1.5% of total revenues in 1H 2024), Echo-Lab achieved a 37% year-on-year growth in revenues in local currency, reaching NGN 1,284 million during the first half of 2024, driven by a 65% year-on-year increase in the average revenue per test. However, test volumes in Nigeria recorded 113 thousand in 1H 2024, down 10% year-on-year due to the continued impact of inflationary pressures affecting patients' purchasing power. In EGP terms, revenues in Nigeria recorded EGP 39 million, down 33% year-on-year, impacted by both lower test volumes and average revenues per test due to the devaluation of the Nigerian Naira.
- Biolab KSA, IDH's newest venture in **Saudi Arabia** (0.2% of total revenues in 1H 2024) began operations in Q1 2024 with one branch opening in January and another in March. The company generated revenues of EGP 339 thousand in 1H 2024, performing 7 thousand tests in 1H 2024 with an average revenue per test of EGP 48. The company continues to run targeted campaigns to attract patients, which is evident through its improved quarterly results. In Q2 2024, the company's revenue reached SAR 281 thousand, compared to SAR 100 thousand in the first quarter of the year, driven by more than a threefold increase in the number of patients tested, as well as a higher average revenue per test. IDH sees significant potential in the Saudi market and continues to actively expand in this region. In EGP terms, Saudi operations reported revenues of EGP 4 million, with an average revenue per test of EGP 579 during the six-month period.
- In Q1 2024, IDH decided to suspend all operations indefinitely in **Sudan** due to the ongoing conflict, leading to the closure of its 18 branches in the country.

### iv. Management Commentary

**Commenting on the Group's performance, IDH Chief Executive Officer Dr. Hend El-Sherbini said:** "I am pleased to report that IDH has successfully built on a strong start to the year, delivering an impressive performance characterized by substantial consolidated revenue growth and improved profitability. This continued upward trajectory highlights the resilience of IDH's business model amid various economic and regional challenges, underscoring our ability to

consistent results and capitalize on opportunities for future growth.

During the first half of 2024, IDH achieved a robust 33% year-on-year revenue increase, driven by a combination of higher test volumes and effective pricing strategies yielding higher average revenues per test. This strong top-line performance, coupled with disciplined cost management, has been pivotal in our solid financial performance across the period. Notably, our success in managing SG&A expenses, which decreased as a share of revenue, underscores our commitment to optimizing costs and enhancing operational efficiency. Consequently, our EBITDA grew by 45% year-on-year, with the margin expanding to 27%, up from 25% last year, highlighting the resilience of our business in adapting to changing economic conditions.

Breaking down our results by regions, our core market in Egypt displayed remarkable resilience, achieving a 37% year-on-year revenue growth. Despite the challenges of rising inflation and its impact on patients' purchasing power, we saw growing demand for our services, with test volumes expanding 10% year-on-year and average revenue per test increasing by 25% year-on-year. We have continued to solidify our market leadership by expanding our service offerings and extending our reach into underpenetrated areas, adding 20 new branches since the beginning of 2024. We are particularly delighted with the progress of our radiology venture, Al-Borg Scan, which remains a central focus of our growth strategy. The expansion of Al-Borg Scan reflects our commitment to enhancing our service offerings in this critical area and aligns with our diversification strategy. These initiatives are yielding tangible results, with the radiology sector now contributing 4.2% to Egyptian revenues, up from 4.2% last year.

In Jordan, geopolitical instability impacted our performance in the first half of the year, resulting in a slight decline in revenue in local currency terms, primarily due to its effect on medical tourism and reduced test volumes. On the other hand, Nigeria saw a robust 37% year-on-year increase in revenue in local currency terms, driven by higher revenue per test. This growth reflects our revenue mix optimization strategy, which has focused on higher-priced tests, along with annual price increases we have implemented to counteract the effects of record-high inflation in the country. However, it is important to note that multiple devaluations of the Nigerian naira over the past two years, coupled with the removal of diesel subsidies, have significantly strained our patients' purchasing power, resulting in decreased test volumes and lower revenues in EGP terms.

Turning to Saudi Arabia, where we officially commenced operations in Q1 2024 with the opening of two branches in Riyadh, our growth has been encouraging. We are excited about expanding in this market, given its favorable demographics, growing population, and rising demand for healthcare services. The diagnostics sector is highly fragmented, with no dominant players, presenting IDH with an excellent environment to implement our proven business model. We are confident that Saudi Arabia will quickly become a key market for IDH. Since our launch, our comprehensive branding strategy, which included outdoor advertising, social media campaigns, community events, sponsorships, and partnerships with local healthcare providers, has yielded strong results. In Q2 2024, our revenue in Saudi Arabia surged to SAR 281 thousand, up from SAR 58 thousand in Q1 2024, driven by a significant increase in patient numbers and higher revenue per test.

Looking ahead, our strategic focus remains steadfast. In Egypt, we expect continued growth driven by recent economic reforms and a gradual improvement in purchasing power. With over four decades of experience in the diagnostics sector, we are particularly excited about the significant potential in our radiology venture. As the economy stabilizes, we see a tremendous opportunity to further capitalize on this growth area, leveraging our enhanced capabilities to deliver greater value across the region. In Saudi Arabia, we are intensifying our efforts to fully capitalize on the market potential, with plans to expand our network of branches across the Kingdom. While we remain mindful of the challenges ahead, particularly in navigating currency fluctuations and inflationary pressures in some of our key markets, our proactive risk management strategies, including price adjustments and cost control measures, have so far mitigated these impacts, and we are confident in our ability to sustain our growth trajectory. As such, we are reaffirming our guidance of approximately 30% revenue growth in FY 2024, with an expected EBITDA margin of around 30% year-on-year, excluding non-recurring expenses and results from our newly inaugurated venture in Saudi Arabia.

Following up on our OTP from the EGX, IDH has received preliminary approval to proceed with the delisting of its shares from the EGX. IDH and the EGX coordinated the process, with the Special Operations Market (OPR) operating from August 22nd to August 28th. During this period, 18,673,728 shares were subscribed. IDH then purchased these shares on August 28th, and the buyback settlement is to be completed by August 28th. Afterwards, IDH will transfer its shares from the EGX to the London Stock Exchange (LSE).

To conclude, our commitment remains unchanged in prioritizing the well-being of our patients and stakeholders and we will continue to deliver exceptional quality care to our growing patient base across Egypt, Jordan, Nigeria, and Saudi Arabia.

- End -

### **Analyst and Investor Call Details**

An analyst and investor call will be hosted at 1pm (UK) | 3pm (Egypt) on Monday, 2 September 2024. You can find more details and register for the call by clicking on this [link](#).

For more information about the event, please contact: [amoataz@EFG-HERMES.com](mailto:amoataz@EFG-HERMES.com)

### **About Integrated Diagnostics Holdings (IDH)**

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology and radiology tests to patients in Egypt, Jordan, Nigeria, Sudan, and Saudi Arabia. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar in Sudan (both in Sudan), and Biolab KSA (Saudi Arabia). With over 40 years of experience, a long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditation. IDH has a portfolio of over 3,000 diagnostics tests. From its base of 601 branches as of 31 December 2023, IDH served over 10 million patients and performed more than 36.1 million tests in 2023. IDH will continue to add laboratories through its Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group targets expansion in appealing markets, including acquisitions in the Middle Eastern, African, and European markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity (i) whose shares are admitted to the equity market (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange (ticker: IDHC) since May 2015, and (ii) with a secondary listing on the Egyptian Exchange since May 2021 (ticker: IDHC.CA).

### **Shareholder Information**

LSE: IDHC.L

EGX: IDHC.CA

Bloomberg: IDHC:LN

Listed on LSE: May 2015

Listed on EGX: May 2021

Shares Outstanding: 600 million

### **Contact**

#### **Tarek Yehia**

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 | [tarek.yehia@idhcorp.com](mailto:tarek.yehia@idhcorp.com)

### **Forward-Looking Statements**


These results for the quarter ended 30 June 2024 have been prepared solely to provide additional information to shareholders and to assess the group's performance in relation to its operations and growth potential. These results should not be relied upon by any other party or for any other reason. This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "aims", "anticipates", "assumes", "believes", "could", "estimates", "expects", "forecasts", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of management", "would" or, in each case their negatives or other similar expressions, which are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding business and management, future growth or profitability and general economic and regulatory conditions and other matters affecting the Group.

Forward-looking statements reflect the current views of the Group's management ("Management") on future events, and are based on the assumptions of the Management and involve known and unknown risks, uncertainties and other factors. These factors could cause the Group's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of any of these assumptions could cause the Group's actual financial condition and results of operations to differ materially from, or fail to meet, the expectations expressed or implied by, such forward-looking statements.

The Group's business is subject to a number of risks and uncertainties that could also cause a forward-looking statement or prediction to differ materially from those expressed or implied by the forward-looking statements contained in this communication. The information, opinions and forward-looking statements contained in this communication speak only as of the date and are subject to change without notice. The Group does not undertake any obligation to review, update, confirm or release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that change in relation to the content of this communication.

## Group Operational & Financial Review

### i. Revenue and Cost Analysis



#### Consolidated Revenue

IDH maintained its strong performance throughout the first half of the year to reach EGP 2,498 million in 1H 2024. Revenue growth was driven by higher test volumes and a 23% increase in average revenue per test, which was supported by higher average revenues per test continued to reflect the strategic pricing in Nigerian operations to counteract mounting inflationary pressure.

	Revenue Analysis 1H 2023
Total revenue (EGP mn)	1,872
	Test Volume Analysis
Total tests (mn)	16.5
	Revenue per Test Analysis
Total revenue per test (EGP)	114

### Revenue by Patient Segment (1H 2024)



### Tests by Patient Segment (1H 2024)



### Revenue Analysis: Contribution by Patient Segment

#### Contract Segment (65% of Group revenue in 1H 2024)

At IDH's contract segment, revenues reached EGP 1,632 million. Average revenue per test grew by 23% year-on-year, reaching EGP 109, which totaled 14.9 million, an 11% increase compared to the same period last year.



The segment also maintained its record-high average tests per patient, recording 4.5 tests in the comparable period last year. This was supported by a 33% increase in revenue per test, which continues to deliver positive results for the Group.

#### Walk-in Segment (35% of Group revenue in 1H 2024)

Meanwhile, in IDH's walk-in segment, revenues reached EGP 866 million, a 28% increase year-on-year, driven by a 33% increase in revenue per test, which reached EGP 301. The segment conducted 2.9 million walk-in tests during the period, a 4% year-on-year decline, shifted to IDH's contract segment. The average tests per patient declined, recording 3.5 tests during the period.

### Detailed Segment Performance Breakdown

	Walk-in Segment			Contract Segment	
	1H23	1H24	Change	1H23	1H24
<b>Revenue (EGP mn)</b>	<b>679</b>	<b>866</b>	<b>28%</b>	<b>1,193</b>	<b>1,632</b>
<b>Patients ('000)</b>	<b>833</b>	<b>814</b>	<b>-2%</b>	<b>3,084</b>	<b>3,305</b>
<i>% of Patients</i>	21%	20%		79%	80%
Revenue per Patient (EGP)	815	1,064	31%	387	494
<b>Tests ('000)</b>	<b>3,008</b>	<b>2,880</b>	<b>-4%</b>	<b>13,457</b>	<b>14,942</b>
<i>% of Tests</i>	18%	16%		82%	84%
Revenue per Test (EGP)	226	301	33%	89	109
Test per Patient	3.6	3.5	-2%	4.4	4.5



## Revenue Analysis: Contribution by Geography

### Egypt (82.8% of Group revenue)

IDH's home and largest market, Egypt, maintained its strong growth of 37% year-on-year, reaching 2,069 million in 1H 2024, a 37% year-on-year increase. Growth was driven by a 10% increase in test volumes as well as a 25% rise in average revenue per test, reflecting the various strategies implemented to counter the inflationary environment.

On a quarterly basis, IDH's Egyptian operations recorded a 38% year-on-year increase of 38% year-on-year.

### AI-Borg Scan

IDH's rapidly growing radiology venture, AI-Borg Scan, continued its growth with revenues reaching EGP 104 million, a substantial 65% year-on-year increase. This is supported by a 33% year-on-year increase in scans performed reaching 12 million. The average revenue per test grew 24% year-on-year to EGP 856, reflecting the expansion of operations through its network of seven branches across the Giza region in the fragmented Egyptian radiology market.

### House Calls

During 1H 2024, IDH's house call services continued its significant growth, constituting 18% of total revenues. This contribution sits at 18% of total revenue, highlighting the segment's growth potential and the effectiveness of its business strategy.


### Wayak

Finally, IDH's Egyptian subsidiary, Wayak, aims to leverage technology to develop electronic medical records and provide personalized services. It achieved revenues of EGP 7 million, marking a 60% year-on-year increase. It processed over 100 thousand orders during the first six months of the year, reflecting strong demand.

## Detailed Egypt Performance Breakdown

Revenue Analysis	
EGP mn	1H 2024
<b>Total Revenue</b>	2,069
Pathology Revenue	1,514
Radiology Revenue	555
<b>Contribution to Consolidated Revenue</b>	
Pathology Revenue	73.5%
Radiology Revenue	26.5%
<b>Test Volume Analysis</b>	
<b>Total Tests</b>	2,400,000
<b>Revenue per Test Analysis</b>	
<b>Total Revenue per Test</b>	862 EGP





### Jordan (15.4% of Group revenue in 1H 2024)

In IDH's second largest market, Jordan, Biolab, recorded revenue of EGP 386 million in 1H 2024, largely attributed to a 2% reduction in test volumes during 1H 2024 due to economic instability in the region. The average revenue per test in Jordan increased 36% year-on-year during the period due to stringent pricing in the region. Biolab booked a 33% year-on-year increase, posting EGP 386 million in 1H 2024, which reflected an 36% year-on-year increase in average revenue per test and a 51% increase in revenue per test due to devaluation of the Egyptian pound.

On a quarterly basis, Biolab recorded JOD 3.3 million in Q2 2024, compared to JOD 3.2 million recorded EGP 221 million, up 51% year-on-year, due to the transactional mix.

### Detailed Jordan Performance Breakdown

Revenue Analysis	
EGP mn	1H 2024
Total Revenue	
Test Volume Analysis	
Total Tests ('000)	1H 2024
Revenue per Test Analysis	
Total Revenue per Test	1H 2024



37%



#### Nigeria (1.5% of Group revenue in 1H 2024)

Echo-Lab, IDH's Nigerian subsidiary, posted a 37% year-on-year increase in revenue, reaching NGN 1,284 million during the first half of 2024. Growth was driven by an increase in revenue per test. Meanwhile, test volumes in Nigeria were down 10% in 1H 2024, as inflationary pressures continued to significantly impact the market. In financial terms, Echo-Lab booked EGP 39 million in revenues during 1H 2024. Despite declining test volumes at the market, average revenue per test increased during the period, reflecting the translation effect from multiple devaluations of the Nigerian Naira.

Quarterly operations in Nigeria generated NGN 682 million, margin of 15.5% for the year. In EGP terms, it amounted to EGP 23 million, reflecting a 37% increase in revenue.

#### Saudi Arabia (0.2% of Group revenue in 1H 2024)

IDH expanded its footprint into Saudi Arabia in the first quarter of 2024, opening a branch in Riyadh, the capital. The first branch opened in January, and IDH is capitalizing on Saudi Arabia's promising demographics, rapidly expanding economy, and offering a considerable opportunity for IDH. The goal of this expansion is to provide comprehensive pathology diagnostic services, with a widespread network of branches across the country.

In its first operational half of the year, Biolab KSA posted revenue of SAR 1,000 thousand tests and booking an average revenue per test of SAR 281 thousand compared to SAR 58 thousand in 2023, representing a threefold increase in the number of patients as well as a higher average revenue per test.

#### Sudan

Due to the ongoing situation in Sudan, which started with the conflict between the Sudanese military and the Sudanese People's Liberation Army, IDH decided to halt all operations in the country starting in Q1 2024. The Sudanese market has now been indefinitely shut down.

#### Revenue Contribution by Country

	1H 2023
<b>Egypt Revenue (EGP mn)</b>	<b>1,514</b>
Pathology Revenue (EGP mn)	1,451
Radiology Revenue (EGP mn)	63
Egypt Contribution to IDH Revenue	80.9%
<b>Jordan Revenue (EGP mn)</b>	<b>290</b>
Jordan Revenues (JOD mn)	6.8

<i>Jordan Revenue Contribution to IDH Revenue</i>	15.5%
<b>Nigeria Revenue (EGP mn)</b>	<b>58</b>
<b>Nigeria Revenue (NGN mn)</b>	<b>937</b>
<i>Nigeria Contribution to IDH Revenue</i>	3.1%
<b>Saudi Arabia Revenue (EGP k)</b>	-
<b>Saudi Arabia Revenue (SAR k)</b>	-
<i>Saudi Arabia Contribution to IDH Revenue</i>	-
<b>Average Exchange Rate</b>	<b>1H 2023</b>
USD/EGP	30.7
JOD/EGP	42.8
NGN/EGP	0.1
SAR/EGP	

#### Patients Served and Tests Performed by Country

	<b>1H 2023</b>
Egypt Patients Served (mn)	3.7
Egypt Tests Performed (mn)	15.1
Jordan Patients Served (k)	183
Jordan Tests Performed (k)	1,180
Nigeria Patients Served (k)	69
Nigeria Tests Performed (k)	136
Saudi Arabia Patients Served (k)	-
Saudi Arabia Tests Performed (k)	-
<b>Total Patients Served (mn)</b>	<b>3.9</b>
<b>Total Tests Performed (mn)</b>	<b>16.5</b>

#### Branches by Country

	<b>30 June 2023</b>
Egypt	531
Jordan	27
Nigeria	12
Saudi Arabia	-
Sudan <sup>[6]</sup>	18
<b>Total Branches</b>	<b>588</b>







## Cost of Goods Sold

IDH reported cost of goods sold at EGP 1,573 million for the first half of 2024, representing a 41% year-on-year increase. As a percentage of revenue, cost of goods sold accounted for 37% in 1H 2024, up from 35% in the same period last year. The reduction in the cost of goods sold was primarily attributed to lower direct wages and salaries, as well as reduced depreciation and amortization costs.

### Cost of Goods sold Breakdown as a Percentage of Revenue

Raw Materials	21.5%
Wages & Salaries	19.5%
Depreciation & Amortisation	14.0%
Other Expenses	31.0%
<b>Total</b>	<b>37.0%</b>

**Raw material costs (34% of consolidated cost of goods sold)** for 1H 2024, totalled EGP 538 million, which represented 34% of the consolidated cost of goods sold. As a percentage of revenue, raw materials stood at 21.5%, at par with the same period last year.


**Wages and salaries including employee share of profits (31% of consolidated cost of goods sold)** remained the second largest contributor to the cost of goods sold, totalled EGP 490 million, a 28% year-on-year increase. As a percentage of revenue, wages and salaries accounted for 19.5%, down from 20.4% in the same period last year. This was primarily due to a 10% reduction in headcount compared to the previous year.

### Direct Wages and Salaries by Region

	1H 2023
Egypt (EGP mn)	287
Jordan (EGP mn)	78
Jordan (JOD mn)	2
Nigeria (EGP mn)	16
Nigeria (NGN mn)	272
Saudi Arabia (EGP mn)	-
Saudi Arabia (SAR k)	-

**Direct depreciation and amortization costs (14% of consolidated cost of goods sold)** for 1H 2024, marking a 20% increase compared to the previous year. The rise in depreciation and amortization costs was primarily due to the expansion of IDH's branch network, which saw the addition of 7 new branches in 1H 2024 compared to 5 in the same period last year.

**Other expenses (21% of consolidated cost of goods sold)** for 1H 2024, totalled EGP 325 million, representing a 32% increase year-on-year. As a percentage of revenues, these expenses accounted for 20.7%, up from 19.5% with the same period last year. The main components of other expenses were maintenance fees, hospital contracts, and cleaning costs.



## Gross Profit

The Company reported a gross profit of EGP 925 million for the first half of 2024, representing a 41% year-on-year increase compared to the previous year. The gross profit margin improved to 37%, up from 35% in 1H 2023. Improved margins were achieved through a 10% increase in the gross profit percentage of revenue, enhancing fixed asset utilization to 100% and a 3% decrease in direct salary expenses relative to revenue.

## Selling, General and Administrative (SG&A) Expenses

SG&A expenses for 1H 2024 totaled EGP 490 million, marking a 10% increase year-on-year. As a percentage of revenues, SG&A accounted for 20%, down from 21% in the same period last year. The decrease in SG&A expenses was mainly due to the following factors:

- Higher indirect wages and salaries reached EGP 100 million, a 10% increase from the previous year. This rise was driven by annual wage increases and the addition of new employees, as well as Saudi Arabian salaries due to a 10% increase in wages as a percentage of revenue decreased to 6% from 7% in the same period last year, due to optimization of IDH's headcount.

## ii. Balance Sheet Analysis







## Assets

### Property, Plant and Equipment

IDH recorded property, plant and equipment (PPE) cost of EGP 2,921 million at the end of 2023. The increase in CAPEX as a share of revenues due to the addition of new branches, renovation of existing branches (constituting 2.5% of revenues), in addition to the translation effect recorded (comprising 12.2% of revenues).

### Total CAPEX Addition Breakdown - 1H 2024

---

Leasehold Improvements/new branches
-------------------------------------

---

AI-Borg Scan Expansion
------------------------

---

<b>Total CAPEX Additions Excluding Translation</b>
--

---

Translation Effect
--------------------

---

<b>Total CAPEX Additions</b>
------------------------------

---

### Trade Receivables and Provisions

Net trade receivables at 30 June 2024 amounted to EGP 753 million, compared to EGP 700 million at year-end 2023. Trade receivables' Days on Hand (DoH) booked 146 days, up from 134 days at year-end 2023.

Provision for doubtful accounts in 1H 2024 was recorded at EGP 17 million, compared to EGP 20 million at year-end 2023. This reduction is attributed to improved economic conditions and higher collections, which have led to a noticeable increase in collected amounts during the period.

### Inventory

At 30 June 2024, IDH booked an inventory balance of EGP 462 million, compared to EGP 450 million at year-end 2023. Meanwhile, Days Inventory Outstanding (DIO) increased to 148 days, up from 138 days at year-end 2023. Increased DIO highlights management's proactive strategy of accumulating inventory to meet market demands and address supply chain pressures.

### Cash and Net Debt

Cash balances and financial assets at amortised cost at 30 June 2024 reached EGP 1,100 million, compared to EGP 1,000 million at year-end 2023.

#### EGP million

---

Treasury Bills
----------------

---

Time Deposits
---------------

---

Current Accounts
------------------

---

Cash on Hand
--------------

---

<b>Total</b>
--------------

---

IDH's net debt<sup>[10]</sup> balance came in at EGP 35 million as of the end of 2023, compared to EGP 100 million at year-end 2023.

#### EGP million

---

Cash and Financial Assets at Amortised Cost <sup>[11]</sup>
---

---

Lease Liabilities Property*
-----------------------------

---

Total Financial Liabilities (Short-term and Long-term)
--

---

Interest Bearing Debt ("Medium Term Loans")
---

---

<b>Net Debt Balance</b>
-------------------------

---

Note: Interest Bearing Debt includes accrued interest for each period.

\*If excluding Lease Liabilities Property (IFRS 16), IDH would have recorded net cash of EGP 100 million.

**Lease liabilities and financial obligations on property** came in at EGP 1,000 million, compared to EGP 900 million at year-end 2023. The increase is attributed to the translation effect of JOD-denominated liabilities and the addition of new branches in EGP in early 2024.

Meanwhile, **financial obligations related to equipment** stood at EGP 1,000 million, compared to EGP 900 million at year-end 2023. The increase is attributable to increases in USD-linked contracts with equipment suppliers and the translation effect of Egyptian Pound.

Finally, **interest bearing debt<sup>[12]</sup>** (excluding accrued interest) reached EGP 111 million at year-end 2023, compared to EGP 111 million at year-end 2023.

## Liabilities

INTEGRATED DIAGNOSTICS HOLDINGS plc - "IDH"  
AND ITS SUBSIDIARIES

# Consolidated Interim Financial Statements

for the quarter ended 30 June 2024

## Consolidated statement of financial position as at 30 June 2024

	Notes	30 June 2024 EGP'000 (Unaudited)
<b>Assets</b>		
<b>Non-current assets</b>		
Property, plant and equipment	4	1,489,713
Intangible assets and goodwill	5	1,783,585
Right of use assets	6	<u>778,462</u>
<b>Total non-current assets</b>		<b>4,051,760</b>
<b>Current assets</b>		
Inventories		462,465
Trade and other receivables	8	960,109

Financial assets at fair value through profit and loss	7	40,134
Financial assets at amortized cost	9	456,902
Cash and cash equivalents	10	797,347
<b>Total current assets</b>		<b>2,716,957</b>
<b>Total assets</b>		<b>6,768,717</b>
<b>Equity</b>		
Share capital		1,072,500
Share premium reserve		1,027,706
Capital reserves		(314,310)
Legal reserve		51,641
Put option reserve	12	(497,838)
Translation reserve		(364,254)
Retained earnings		1,810,855
<b>Equity attributable to the owners of the Company</b>		<b>2,786,300</b>
Non-controlling interests		765,517
<b>Total equity</b>		<b>3,551,817</b>
<b>Non-current liabilities</b>		
Provisions		20,635
Borrowings	13	53,972
Other financial obligations	14	959,217
Non-current put option liability	12	41,733
Deferred tax liabilities	19-C	433,912
<b>Total non-current liabilities</b>		<b>1,509,469</b>
<b>Current liabilities</b>		
Trade and other payables	11	816,631
Other financial obligations	14	220,469
Current put option liability	12	456,105
Borrowings	13	40,105
Current tax liabilities		174,121
<b>Total current liabilities</b>		<b>1,707,431</b>
<b>Total liabilities</b>		<b>3,216,900</b>
<b>Total equity and liabilities</b>		<b>6,768,717</b>

The accompanying notes form an integral part of these consolidated financial statements.

This condensed consolidated interim financial information was approved and authorised for issue by the Board of Directors and signed on their behalf

---

Dr. Hend El Sherbini  
Chief Executive Officer

Independent

## Consolidated income statement for the quarter ended 30 June 2024

	Notes	
Revenue	21	
Cost of sales		
<b>Gross profit</b>		<hr/>
Marketing and advertising expenses		
Administrative expenses	16	
Impairment loss on trade and other receivable		
Other (expenses)/income		
<b>Operating profit</b>		<hr/>
Net fair value losses on financial assets at fair value	17	
Finance costs	18	
Finance income	18	
<b>Net finance (costs)/income</b>		<hr/>
<b>Profit before income tax</b>		<hr/>
Income tax expense	19-B	
<b>Profit for the period</b>		<hr/> <hr/>
<b>Profit attributed to:</b>		
Owners of the Company		
Non-controlling interests		<hr/>
<b>Earnings per share</b>	21	<hr/> <hr/>
Basic and diluted		

The accompanying notes form an integral part of these consolidated financial statements.

## Consolidated statement of comprehensive income for the quarter ended 30 2024

### Net profit for the period

Items that may be reclassified to profit or loss:

Exchange difference on translation of foreign operations

**Other comprehensive income for the period, net of tax**

**Total comprehensive income for the period**

### Attributable to:

Owners of the Company

Non-controlling interests

## Consolidated statement of cash flows for the quarter ended 30 June 2024

	Note	30 2 EO (Un
<b>Cash flows from operating activities</b>		
Profit before tax		
<b>Adjustments for:</b>		
Depreciation of property, plant and equipment	4	
Depreciation of right of use assets	6	
Amortisation of intangible assets	5	
Interest income	17	
Interest expense	17	
Bank Charges		
Gain on disposal of Property, plant and equipment		
Impairment in trade and other receivables		
Equity settled financial assets at fair value		
ROU Asset/Lease Termination		
Unrealised foreign currency exchange (gains) losses	17	
FV Through P&L		

Change in Provisions		
Change in Inventories		
Change in trade and other receivables		
Change in trade and other payables		
<b>Net cash generated from operating activities</b>		
Tax paid during period		
<b>Net cash generated from operating activities</b>		
<b>Cash flows from investing activities</b>		
Interest received on financial asset at amortised cost		
Payments for the purchase of financial assets at amortized cost		
Proceeds for the sale of financial assets at amortized cost		
Payments for acquisition of property, plant and equipment		4
Payments for acquisition of intangible assets		5
Proceeds from sale of Property, plant and equipment		
Payment for purchase of global depository receipts (short-term investment)		17
Proceeds from sale of global depository receipts (short-term investments)		17
<b>Net cash flows generated (used in) from investing activities</b>		
<b>Cash flows from financing activities</b>		
Proceeds from borrowings		
Repayments of borrowings		
Interest paid		
Bank charges paid		
Payment of finance lease liabilities		
Cash injection by owner of non-controlling interest		
<b>Net cash flows used in financing activities</b>		
<b>Net (decrease) increase in cash and cash equivalents</b>		
Cash and cash equivalents at the beginning of the year		
Effect of exchange rate		
<b>Cash and cash equivalents at the end of the period</b>		10

**Non-cash investing and financing activities disclosed in other notes are:**

- €€€€€ acquisition of right-of-use assets - note 6
- €€€€€ Property, plant and equipment - note 4
- €€€€€ Put option liability - note 12

The accompanying notes on pages 7 - 22 form an integral part of these consolidated financial statements.

## Consolidated statement of changes in equity for the quarter ended 30 June 2024

EGP'000	Share Capital	Share premium reserve	Capital reserves	Legal reserve*	P re
<b>Balance at 1 January 2023</b>	<b>1,072,500</b>	<b>1,027,706</b>	<b>(314,310)</b>	<b>51,641</b>	
Profit for the period	-	-	-	-	-
Other comprehensive income for the period	-	-	-	-	-
<b>Total comprehensive income at 31 March 2024</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Contributions and distributions</b>					
Movement in put option liabilities	-	-	-	-	-

Non-controlling interests cash injection in subsidiaries during the period	-	-	-	-
<b>Total contributions and distributions</b>	-	-	-	-
<b>Balance at 30 June 2024 (Unaudited)</b>	<b>1,072,500</b>	<b>1,027,706</b>	<b>(314,310)</b>	<b>51,641</b>
<b>Balance at 1 January 2023</b>	<b>1,072,500</b>	<b>1,027,706</b>	<b>(314,310)</b>	<b>51,641</b>
Profit for the period	-	-	-	-
Other comprehensive loss for the period	-	-	-	-
<b>Total comprehensive income at 31 March 2023</b>	-	-	-	-
<b>Transactions with owners of the Company</b>				
<b>Contributions and Distributions</b>				
Movement in put option liabilities	-	-	-	-
<b>Total contributions and distributions</b>	-	-	-	-
<b>Balance at 30 June 2023 (Unaudited)</b>	<b>1,072,500</b>	<b>1,027,706</b>	<b>(314,310)</b>	<b>51,641</b>

\* Under Egyptian Law each subsidiary must set aside at least 5% of its annual net profit into a legal reserve until such time that this represents 50% of each subsidiary's net profit.

The accompanying notes on pages 7 - 22 form an integral part of these consolidated financial statements.

(In the notes all amounts are shown in Egyptian Pounds "EGP'000" unless otherwise stated)

## 1. Reporting entity

Integrated Diagnostics Holdings plc "IDH" or "the Company" is a Company which was incorporated in Jersey on 4 December 2015 and established according to the provisions of the Companies (Jersey) Law 1991 under Registered No. 117257. These condensed consolidated interim financial information as of and for the six months ended 30 June 2024 comprise the Company and its subsidiaries (referred as the 'Group'). The Company is a dually listed entity, in both London Stock Exchange (since 2015) and in the Egyptian Stock Exchange (during May 2021).

The principal activities of the Company and its subsidiaries (together "The Group") include investments in all types of the health care of medical diagnostics (the key activities are pathology and Radiology related tests), either through acquisitions of related entities in different jurisdictions or through expanding the acquired investments they have. The key jurisdictions that the Group operates in are Egypt, Jordan, Nigeria, Sudan and Saudi Arabia.

The Group's financial year starts on 1 January and ends on 31 December of each year.

This condensed consolidated interim financial information was approved for issue by the Directors of the Company on 28 August 2024.

## 2. Basis of preparation

### A) Statement of compliance

These condensed consolidated interim financial information have been prepared as per IAS 34 'Interim Financial Reporting' (as amended by the IASB), as the accounting policies adopted are consistent with those of the previous financial year ended 31 December 2023 corresponding interim reporting period.

These condensed consolidated interim financial information do not include all the information and disclosures in the annual consolidated financial Statement, and should be read in conjunction with the financial Statement published as at and for the year ended 31 December 2023 which is available at [www.idhcorp.com](http://www.idhcorp.com). In addition, results of the six months period ended 30 June 2024 are not necessarily indicative for the results that may be expected for the financial year ending 31 December 2024.

### B) Basis of measurement

The condensed consolidated interim financial information has been prepared on the historical cost basis except where otherwise stated. The Group mandates that fair value accounting is required which is related to the financial assets and liabilities measured at fair value.

### C) Functional and presentation currency



These condensed consolidated interim financial information is presented in Egyptian Pounds (EGP'000). The functional currency of the majority of the Group's entities is the Egyptian Pound (EGP) and is the currency of the primary economic environment in which it operates.

The Group also operates in Jordan, Sudan, Nigeria and Saudi Arabia and the functional currencies of those foreign operations are the currencies of those respective territories, however due to the size of these operations, there is no significant impact on the functional currency of the Group, which is the Egyptian Pound (EGP).

### 3. Significant accounting policies

In preparing these condensed consolidated interim financial information, the significant judgments made by the management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that were applied to the consolidated financial statements for the year ended 31 December 2023."The preparation of these condensed consolidated interim financial information requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the resulting amounts of assets, liabilities, income and expense. Actual results may differ from these estimates. Information about significant estimation uncertainty and critical judgement in applying accounting policies that have the most significant effect on the amounts recognised in the condensed consolidated interim financial statement is described in note 3.2 of the annual consolidated financial statements published for the year ended 31 December 2023. In preparing these condensed consolidated interim financial information, the significant judgments made by the management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that were applied to the consolidated financial statements for the year ended 31 December 2023".

### 4. Property, plant and equipment

	Land & buildings	Medical, electric & information system equipment	Leasehold improvements
<b>Cost</b>			
At 1 January 2024	460,869	1,254,894	
Additions	-	44,180	
Disposals	-	(2,741)	
Exchange differences	24,665	122,127	
Transfers	-	-	
<b>Balance at 30 June 2024</b>	<b>485,534</b>	<b>1,418,460</b>	
<b>Depreciation</b>			
At 1 January 2024	69,311	655,649	
Depreciation for the period	4,200	79,895	
Disposals	-	(1,998)	
Exchange differences	2,499	73,725	
<b>Balance at 30 June 2024</b>	<b>76,010</b>	<b>807,271</b>	
<b>Net book amount</b>			
<b>At 30 June 2024 (Unaudited)</b>	<b>409,524</b>	<b>611,189</b>	
<b>At 31 December 2023</b>	<b>391,558</b>	<b>599,245</b>	

## 5. Intangible assets and goodwill

Intangible assets represent goodwill acquired through business combinations and brand names.

	<b>Goodwill</b>	<b>Brand name</b>
<b>Cost</b>		
<b>Balance at 1 January 2024</b>	<b>1,304,967</b>	<b>403,461</b>
Additions	-	-
Disposals	-	-
Exchange differences	50,375	22,093
<b>Balance at 30 June 2024</b>	<b>1,355,342</b>	<b>425,554</b>
<b>Amortisation</b>		
<b>Balance at 1 January 2024</b>	<b>17,718</b>	<b>392,135</b>
Amortisation	-	-
Disposals	-	-
Exchange differences	(127)	37
<b>Balance at 30 June 2024</b>	<b>17,591</b>	<b>425,172</b>
<b>Net book amount</b>		
<b>At 30 June 2024(Unaudited)</b>	<b>1,337,751</b>	<b>425,125</b>
<b>At 31 December 2023</b>	<b>1,287,249</b>	<b>403,065</b>

Goodwill impairment reviews are undertaken annually or more frequently if events or changes in circumstances indicate impairment. No indicators of impairment have been identified during the six months ended 30 June 2024.

## 6. Right-of-use assets

	<b>30 June 2024</b>
	<b>(Unaudited)</b>
Balance at 1 January	68
Addition for the period / year	4
Depreciation charge for the period / year	(8)
Terminated contracts	(
Exchange differences	13
<b>Balance</b>	<b>77</b>

## 7. Financial asset at fair value through profit or loss

	<b>30 June 2024</b>
	<b>(Unaudited)</b>
Current equity investments	40
	<b>40</b>

\* On August 17, 2017, Almakhabariyoun AL Arab (seller) has signed IT purchase Agreement with JSC Mega Lab to transfer and install the Laboratory Information Management System (LIMS) for a purchase price amounted to USD 4,000,000, which will be in the form of 10% equity stake in JSC Mega Lab. In case the valuation of the project is less or USD 4,000,000, the seller stake will be adjusted accordingly, in a way that the seller equity stake shall not fall below 10% in JSC Mega Lab.

- Ownership percentage in JSC Mega Lab at the transaction date on April 8, 2019, and as of June 30, 2024, was 10%.

- On April 8, 2019, Al Mokhabariyoun Al Arab (Biolab) has signed a Shareholder Agreement with JSC Mega Lab, JSC Georgia Healthcare Group (CHG), whereas, BioLab Shall have a put option, exercisable within 12 months immediately after the expiration of five(5) year period from the signing date, which allows BioLab stake to be bought out by CHG at a price of equity value being USD 400,000 plus 15% annual Interred Rate of Return (IRR).

- If JCI accreditation is not obtained, immediately after the expiration of the 12 months period, CHG shall have a call option (the Accreditation Call option), exercisable within 6 months period, allowing CHG to purchase BioLab's Stake in JSC Mega Lab at a price of the equity value of USD 400,00.00 plus the 20% annual IRR.

- After 12 months from the date of the put option period expiration, CHG to purchase Biolab's Stake in JSC Mega Lab having value of USD 400,000 plus higher of 20% annual IRR or 6X EV/EBITDA (of the financial year immediately after the call option exercise date).

- In case the Management Agreement or the Purchase Agreement and/or the Service level Agreement is terminated/cancelled within 6 months period from the date of such termination/cancellation, CHG shall have a call option, exercisable within 6 months period, allowing the CHG to purchase Biolab's Strake in JSC Megalab having value of USD 400,000.00 plus 20% annual Interred Rate of Return (IRR).

## 8. Trade and other receivables

	<b>30 June 2024</b>
	<b>(Unaudited)</b>
Trade receivables - net*	753
Prepayments	73
Due from related parties note (15)	3
Other receivables - net*	128
Accrued revenue	1
	<b>960</b>

\* The expected credit loss related to trade and other receivables was EGP 216,111K (2023: EGP 191,580K). Below show the in the provision for impairment of trade and other receivables:

	<b>30 June 2024</b>
	<b>(Unaudited)</b>
<b>Balance at 1 January</b>	191,580
Charge for the period	17,200
Exchange differences	7,330
	<b>216,110</b>

## 9. Financial assets at amortised cost

	<b>30 June 2024</b>
	<b>(Unaudited)</b>
Term deposits (more than 3 months)	308
Treasury bills (more than 3 months)	148
	<b>456</b>

The maturity date of the treasury bills and Fixed-term deposits are between more than 3 months and 12 months and have average interest rates of EGP 26.51% and Fixed-term deposits more than 3 months have average interest rates of EGP and JOD 5.38% respectively.

## 10. Cash and cash equivalents

**30 June 2024**  
**(Unaudited)**

Cash at banks and on hand	675,846
Treasury bills (less than 3 months)	108,058
Term deposits (less than 3 months)	13,443
	<b>797,347</b>
	<b>797,347</b>

Cash at banks earns interest at floating rates based on daily bank deposit rates. Short-term deposits and treasury bills are made for varying periods of between one day and six months, depending on the immediate cash requirements of the Company and earn interest at the respective weighted average rate. Of the above Short-term deposits relate to amounts held in Jordan with a weighted average rate of 17.71% (2023: 16.40%), Short-term deposits relate to amounts held in Jordan with a weighted average rate of 5% (2023: 5%) and Short-term deposits relates to amounts held in Nigeria with a weighted average rate of 5.6% (2023:5.6%). Treasury bills are denominated in EGP and earn interest at a weighted average rate of 24.95% (2023: 24.95%) per annum.

### 11. Trade and other payables

	<b>30 June 2024</b>
	<b>(Unaudited)</b>
Trade payable	283,469
Accrued expenses	271,318
Due to related parties note (15)	8,191
Other payables	163,455
Deferred revenue	80,517
Accrued finance cost	9,681
	<b>816,631</b>
	<b>816,631</b>

### 12. Put option liability

	<b>30 June 2024</b>
	<b>(Unaudited)</b>
Current put option - Biolab Jordan	444,288
Current put option - Eagle Eye-Echo scan	11,817
	<b>456,105</b>
	<b>456,105</b>
	<b>30 June 2024</b>
	<b>(Unaudited)</b>
Non-current put option - Medical Health Development	41,733
	<b>41,733</b>
	<b>41,733</b>

## 12. Put option liability (continued)

### Put option - Biolab Jordan

The accounting policy for put options after initial recognition is to recognise all changes in the carrying value of the put option within equity.

Through the historic acquisitions of Makhbaryoun Al Arab the Group entered into separate put option arrangements to purchase remaining equity interests from the vendors at a subsequent date. At acquisition, a put option liability has been recognised at the present value of the exercise price of the option.

The option is calculated at seven times EBITDA of the last 12 months minus Net Debt and its exercisable in whole starting on the anniversary of completion of the original purchase agreement, which fell due in June 2016. The vendor has not exercised this option by June 2024. It is important to note that the put option liability is treated as current as it could be exercised at any time by the vendor. However, based on discussions and ongoing business relationships, there is no expectation that this will happen in next 18 months. The option has no expiry date.

### Put option - Eagle Eye-Echo scan

According to the definitive agreements signed on 15 January 2018 between Dynasty Group Holdings Limited and the Inception Finance Corporation (IFC) related to the Eagle Eye-Echo scan transaction, IFC has the option to purchase its shares to Dynasty in the future. The put option price will be calculated on the basis of the fair market value determined by an independent valuator.

### Put option - Medical Health Development

Based on the agreement made on October 27th, 2022, between Business Flower Holding LLC, Integrated Diagnostics Holding LLC and Al Makhbaryoun Al Arab there is a clause that in cases of bankruptcy and defaulting, a non-defaulting party is entitled to implement one of the following options for a defaulting party's share without reference to it:

- (A) sell to the Non-Defaulting Party its Shares at the Fair Price of such Shares.
- (B) buy the Non-Defaulting Party's Shares at the Fair Price of such Shares.
- (C) requesting the dissolution and liquidation of the Company.

It's important to note that the put option, which grants these rights to the non-defaulting party, does not have an expiration date.

## 13. Loans and borrowings

	Currency	Nominal interest rate	Maturity
AUB ??? BANK	EGP	CBE corridor rate*+1%	26 January 2027
AUB - BANK	EGP	Secured 5%	3 April 2025
Bank: Sterling BANK	NGN	Secured 22%	26 May 2024

Amount held as:

Current liability

Non- current liability

A) In July 2018, AL-Borg lab, one of IDH subsidiaries, was granted a medium-term loan amounting to EGP 130.5m from United Bank "AUB Egypt" to finance the investment cost related to the expansion into the radiology segment. As of 30 June 2024 only EGP 124.9 M had been drawn down from the total facility available with 43.9 M had been repaid. The loan is fully repaid by January 2027.

The loan contains the following financial covenants which if breached will mean the loan is repayable on demand:

1. The financial leverage shall not exceed 0.7 throughout the period of the loan.  
"**Financial leverage**": total bank debt divided by net equity.
2. The debt service ratios (DSR) shall not be less than **1.35 starting 2020**  
"**Debt service ratio**": cash operating profit after tax plus depreciation for the financial year less annual maintenance of machinery and equipment adding cash balance (cash and cash equivalent) divided by total financial payments.  
"**Cash operating profit**": Operating profit after tax, interest expense, depreciation and amortisation, is calculated as Net income after tax and unusual items adding Interest expense, Depreciation, Amortisation and provisions excluding related provisions less interest income and Investment income and gains from extraordinary items.  
"**Financial payments**": current portion of long-term debt including finance lease payments, interest expense and dividends distributions.
3. The current ratios shall not be less than 1.  
"**Current ratios**": Current assets divided current liabilities.

The terms and conditions of outstanding loans are as follows:

\* As at 30 June 2024 corridor rate 28.25% (2023: 20.25%)

AL- Borg company didn't breach any covenants for MTL agreements.

#### 14. Other financial obligations

	<b>30 June 2024</b>
	<b>(Unaudited)</b>
Financial liability- laboratory equipment	236,046
Lease liabilities building	943,640
	<b>1,179,686</b>

The un-discounted financial obligations for the laboratory equipment and building are as follows:

	<b>30 June 2024</b>
	<b>Minimum payments</b>

	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Less than one year	345,934	1,060,303
Between one and five years	1,060,303	256,100
More than five years	256,100	<b>1,662,337</b>
	<b>1,662,337</b>	<b>4,000,000</b>

		<b>31 Dec 2024</b>
	<b>Minimum payments</b>	<b>(Audited)</b>
Less than one year	291,342	1,054,902
Between one and five years	1,054,902	166,965
More than Five years	166,965	<b>1,513,209</b>
	<b>1,513,209</b>	<b>4,000,000</b>

**Amounts recognised in profit or loss:**

	<b>2024</b>
	<b>(Unaudited)</b>
Interest on lease liabilities	53,820
Expenses related to short-term lease	3,200
	<b>57,020</b>

**15. Related party transactions**

The significant transactions with related parties, their nature volumes and balance during the period 30 June 2024 are as follows:

<b>Related Party</b>	<b>Nature of transaction</b>	<b>Nature of relationship</b>	<b>Tr</b>
International Fertility (IVF)**	Expenses paid on behalf	Affiliate	
H.C Security	Provide service	Entity owned by Company's board member	



Life Health Care	Provided service	Entity owned by Company's CEO
Dr. Amid Abd Elnour	Put option liability	Bio. Lab C.E.O and shareholder
	Current account	Bio. Lab C.E.O and shareholder
International Finance corporation (IFC)	Put option liability	Echo-Scan shareholder
Hena Holdings Ltd	shareholders' dividends deferral agreement	shareholder
Actis IDH Limited	shareholders' dividends deferral agreement	shareholder
Business Flowers Holding	Put option liability	shareholder

#### 15. Related party transactions (continued)

<b>Related Party</b>	<b>Nature of transaction</b>	<b>Nature of relationship</b>
AL borg Scan (S.A.E)*	Expenses paid on behalf	Affiliate
International Fertility (IVF)**	Expenses paid on behalf	Affiliate
H.C Security	Provide service	Entity owned by Company's board member

Life Health Care	Provided service	Entity owned by Company's CEO
Dr. Amid Abd Elnour	Put option liability	Bio. Lab C.E.O and shareholder
	Current account	Bio. Lab C.E.O and shareholder
International Finance corporation (IFC)	Put option liability	Echo-Scan shareholder
International Finance corporation (IFC)	Current account	Echo-Scan shareholder
Integrated Treatment for Kidney Diseases (S.A.E)	Rental income	Entity owned by Company's CEO
	Medical Test analysis	
HENA HOLDINGS LTD	shareholders' dividends deferral agreement	Shareholder
ACTIS IDH LIMITED	shareholders' dividends deferral agreement	Shareholder
Business Flowers Holding	Put option liability	Shareholder

\* ALborg Scan is a company whose shareholders include Dr. Moamena Kamel (founder of IDH subsidiary Al-Mokhtabar Lab)

\*\* International Fertility (IVF) is a company whose shareholders include Dr. Moamena Kamel (founder of IDH subsidiary Al-Labs).

## 15. Related party transactions (continued)

### Compensation of key management personnel of the Group

The amounts disclosed in the table are the amounts recognised as an expense during the reporting period related to key management personnel.

Short-term employee benefits

**30 June 2024**

**(Unaudited)**

## 16. General and administrative expenses

	2024
	(Unaudited)
Wages and salaries	135,287
Depreciation	16,726
Amortisation	4,134
Consulting fees	102,942
Other expenses	72,442
<b>Total</b>	<b>331,531</b>

## 17. Fair value losses on financial assets at fair value through profit or loss

During the two quarter of 2024, Integrated Diagnostics Holdings Limited company invested in Global Depository Receipt (GDR) in stock exchanges, where the companies purchased 1.97 million shares, EGP 152 M from the Egyptian Stock Exchange and during the same period on the London Stock exchange at USD 2.99 M excluding the transaction cost.

	Number of shares'000
listed equity securities	Shares bought 1,970
	Shares sale 1,970

## 18. Net finance cost

	2024
	(Unaudited)
<b>Finance income</b>	<b>290,540</b>
Interest income	54,000
Net foreign exchange gain	290,540
<b>Total finance income</b>	<b>351,540</b>
<b>Finance cost</b>	<b>351,540</b>

Fast Track Payment	(3,)
Bank charges	(6,
Interest expense	(78
<b>Total finance cost</b>	<b>(88</b>
<b>Net finance income</b>	<b>26</b>

The increase is mainly driven by the change of exchange rate between EGP and other currencies that took place in June 2023 which resulted into foreign exchange gain during the period ended 30 June 2024.

## 19. Tax

### A) Tax expense

Tax expense is recognised based on management's best estimate of the weighted-average annual income tax rate expected for the financial year multiplied by the pre-tax income of the interim reporting period.

### B) Income tax

Amounts recognised in profit or loss as follow:

	<b>For the 2024</b>
	<b>(Unaudited)</b>
<b>Current tax:</b>	
Current period	(149,628)
Current tax	<b>(149,628)</b>
<b>Deferred tax:</b>	
Deferred tax arising on undistributed reserves in subsidiaries	(55,063)
Deferred tax relating to origination and reversal of temporary differences	(2,619)
<b>Total Deferred tax expense</b>	<b>(57,682)</b>
<b>Tax expense recognised in profit or loss</b>	<b>(207,310)</b>

### C) Deferred tax liabilities

Deferred tax relates to the following:

	<b>30 June 2024</b>
	<b>(Unaudited)</b>
Property, plant and equipment	(35,812)
Intangible assets	(119,068)
Undistributed reserves from Group subsidiaries	(281,938)
Provisions	2,906

Net deferred tax liabilities

(433,912)

## 20. Financial instruments

The Group has reviewed the financial assets and liabilities held at 30 June 2024. It has been deemed that the carrying amount of financial instruments are a reasonable approximation of fair value. All financial instruments are deemed Level 3.

## 21. Earnings per share

Profit attributed to owners of the parent

Weighted average number of ordinary shares in issue

**Basic and diluted earnings per share**

2024

(C)

The Company has no potential diluted shares as at 30 June 2024 and 30 June 2023, therefore the earnings per diluted share are equal to basic earnings per share.

## 22. Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments. The chief operating decision-maker is identified as the steering committee that makes strategic decisions.

The Group has five operating segments based on geographical location as the Group's Chief Operating Decision Maker (CODM) uses the internal management reports and KPIs of each geography.

The Group operates in five geographic areas, Egypt, Sudan, Jordan, Nigeria and Saudi Arabia. As a provider of medical services, IDH's operations in Sudan are not subject to sanctions. The revenue split, EBITDA split (being the key profit measure used by CODM) net profit and loss between the five regions is set out below.

For the six months ended	Revenue by geographic location			
	Egypt region	Sudan region	Jordan region	Nigeria region
30 June 2024 (Unaudited)	2,069,240	-	385,837	3,053,087
30 June 2023 (Unaudited)	1,513,673	10,194	290,255	5,016,120

For the six months ended	EBITDA by geographic location			
	Egypt region	Sudan region	Jordan region	Nigeria region
30 June 2024 (Unaudited)	691,994	(44)	88,712	(13,500)
30 June 2023 (Unaudited)	406,862	1,249	68,502	(15,000)

## 22. Segment reporting (continued)

For the six months ended	Net profit / (loss) by geographic location			
	Egypt region	Sudan region	Jordan region	Nigeria region
30 June 2024 (Unaudited)	560,010	11,033	5,343	(11,000)
30 June 2023 (Unaudited)	225,921	3,637	11,312	(29,000)

	Non-current assets by geographic location			
	Egypt region	Sudan region	Jordan region	Nigeria region
30 June 2024 (Unaudited)	3,024,006	5,999	881,668	39,510
31 December 2023	3,091,485	3,848	609,699	47,630

The operating segment profit measure reported to the CODM is EBITDA, as follows:

	2024
<b>Profit from operations</b>	(Unaudited)
Property, plant and equipment depreciation	
Right of use depreciation	
Amortization of Intangible assets	
<b>EBITDA</b>	
Non-recurring expenses	

### 23. Significant events during the period

The Monetary Policy Committee of the Central Bank of Egypt decided to raise the deposit and lending interest rates by 200 b on 1 February 2024, then by 600 basis points on 6 March 2024. The credit and discount rates were also raised by 600 basis p March 2024.

The Central Bank of Egypt announced that it would allow the foreign exchange rate to be determined. against the Egyptian pound as per market mechanisms, starting from 6 March 2024.

Integrated Diagnostics Holdings plc "IDH" at the Company's Extraordinary General Meetings held on 12 June 20 July 2024, the company approved the exit from the Egyptian Stock Exchange of its ordinary shares from the Egypt Exchange. Following up on our delisting from the EGX, IDH has received preliminary approval to proceed with the of its shares. IDH and the EGX coordinated the process, with the Special Operations Market (OPR) operating from 18th to August 22nd. During this period, 18,673,728 shares were subscribed. IDH then purchased these shares o 26th, and the buyback settlement is to be completed by August 28th. Afterwards, IDH will transfer its shares from to the London Stock Exchange (LSE).

---

[1] EBITDA is calculated as operating profit plus depreciation and amortization.

[2] Cash balance includes time deposits, treasury bills, current accounts, and cash on hand.

[3] Key operational indicators are calculated based on revenues for the periods of EGP 2,498 million and EGP 1,872 million for 1H 2024 and 1H 2023, respectively.

[4] IDH rolled out 20 new branches in Egypt and 2 in KSA, while closing 1 branch in Jordan over the past 12-month period. It is important to note that due to the ongoing conflict in branches in the country have been shut down, leading to a net growth in its branch network of 3 branches.

[5] EBITDA is calculated as operating profit plus depreciation and amortization.

[6] Due to the ongoing conflict in Sudan, IDH has terminated operations in the country, with the closure of all 18 branches.

[7] Interest expenses on medium-term loans include EGP 11 million related to the Group's facility with Ahli United Bank Egypt (AUBE).

[8] IDH's interest bearing debt as at 30 June 2024 included EGP 91 million to its facility with Ahli United Bank Egypt (AUBE) (outstanding loan balances are excluding accrued in worth noting that in order to finance the early repayment settlement with General Electric, the Company utilized a bridge loan facility of EGP 55 million. The facility was withdrawn in Q2 2023

[9] Interest expenses on medium-term loans include EGP 11 million related to the Group's facility with Ahli United Bank Egypt (AUBE).

[10] The net debt balance is calculated as cash and cash equivalent balances including financial assets at amortised cost, less interest-bearing debt (medium term loans), financial liabilities.

[11] As outlined in Note 9 of IDH's Consolidated Financial Statements, some term deposits and treasury bills cannot be accessed for over 3 months and are therefore not treated which cannot be accessed for over 3 months stood at EGP 309 million at June 2024 (2023: EGP 49 million). Meanwhile, treasury bills not accessible for over 3 months stood at EGP 112 million).

[12] IDH's interest bearing debt as at 30 June 2024 included EGP 91 million to its facility with Ahli United Bank Egypt (AUBE) (outstanding loan balances are excluding accrued in is worth noting that in order to finance the early repayment settlement with General Electric, the Company utilized a bridge loan facility of EGP 55 million. The facility was withdrawn in Q2 2023.

[13] Accounts payable is calculated based on average payables at the end of each period.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IR BIGDIXSDDGSR